Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2019 6
2020 5
2021 1
2022 1
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies.
Saygin C, Roloff G, Hahn CN, Chhetri R, Gill S, Elmariah H, Talati C, Nunley E, Gao G, Kim A, Bishop M, Kosuri S, Das S, Singhal D, Venugopal P, Homan CC, Brown A, Scott HS, Hiwase D, Godley LA. Saygin C, et al. Among authors: chhetri r. Blood Adv. 2023 Feb 28;7(4):549-554. doi: 10.1182/bloodadvances.2022008172. Blood Adv. 2023. PMID: 36001442 Free PMC article.
TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.
Shah MV, Tran ENH, Shah S, Chhetri R, Baranwal A, Ladon D, Shultz C, Al-Kali A, Brown AL, Chen D, Scott HS, Greipp P, Thomas D, Alkhateeb HB, Singhal D, Gangat N, Kumar S, Patnaik MM, Hahn CN, Kok CH, Tefferi A, Hiwase DK. Shah MV, et al. Among authors: chhetri r. Blood Cancer J. 2023 Apr 11;13(1):51. doi: 10.1038/s41408-023-00821-x. Blood Cancer J. 2023. PMID: 37041128 Free PMC article.
Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms.
Shah MV, Chhetri R, Dholakia R, Kok CH, Gangat N, Alkhateeb HB, Al-Kali A, Patnaik MM, Baranwal A, Greipp PT, He R, Begna KH, Tiong IS, Wei AH, Hiwase D. Shah MV, et al. Among authors: chhetri r. Am J Hematol. 2022 Aug;97(8):1013-1022. doi: 10.1002/ajh.26589. Epub 2022 May 27. Am J Hematol. 2022. PMID: 35560061 Free PMC article.
TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype.
Hiwase D, Hahn C, Tran ENH, Chhetri R, Baranwal A, Al-Kali A, Sharplin K, Ladon D, Hollins R, Greipp P, Kutyna M, Alkhateeb H, Badar T, Wang P, Ross DM, Singhal D, Shanmuganathan N, Bardy P, Beligaswatte A, Yeung D, Litzow MR, Mangaonkar A, Giri P, Lee C, Yong A, Horvath N, Singhal N, Gowda R, Hogan W, Gangat N, Patnaik M, Begna K, Tiong IS, Wei A, Kumar S, Brown A, Scott H, Thomas D, Kok CH, Tefferi A, Shah MV. Hiwase D, et al. Among authors: chhetri r. Blood. 2023 Mar 2;141(9):1087-1091. doi: 10.1182/blood.2022018236. Blood. 2023. PMID: 36574363 Free article. No abstract available.
IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation.
Hong LE, Wechalekar MD, Kutyna M, Small A, Lim K, Thompson-Peach C, Li JJ, Chhetri R, Scott HS, Brown A, Hahn CN, Yeung DT, Sajid S, Robinson N, Thomas R, Branford S, D'Andrea RJ, Samaraweera SE, Patnaik M, Proudman S, Thomas D, Kok CH, Shah MV, Hiwase DK. Hong LE, et al. Among authors: chhetri r. Blood. 2024 May 2;143(18):1873-1877. doi: 10.1182/blood.2023023593. Blood. 2024. PMID: 38457663 Free article.
18 results